PMID- 12743330
OWN - NLM
STAT- MEDLINE
DCOM- 20040227
LR  - 20181130
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 21
IP  - 3
DP  - 2003
TI  - A new type I IFN-mediated pathway for the rapid differentiation of monocytes into 
      highly active dendritic cells.
PG  - 357-62
AB  - Dendritic cells (DCs) are a unique leukocyte type consisting of different subsets 
      of professional antigen-presenting cells. Since DCs initiate and govern the 
      immune response, they represent an ideal target for intervention aimed at 
      modulating and potentiating immune responses against cancer and infectious 
      diseases. We recently described and characterized, at a functional level, a novel 
      DC subset, interferon (IFN)-DCs, derived from blood monocytes after a short 
      exposure to type I IFN and GM-CSF. Here, we review our recent studies on IFN-DCs 
      and discuss their possible use in clinical immunotherapeutic strategies.
FAU - Santini, S M
AU  - Santini SM
AD  - Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy. ssant@iss.it
FAU - Di Pucchio, T
AU  - Di Pucchio T
FAU - Lapenta, C
AU  - Lapenta C
FAU - Parlato, S
AU  - Parlato S
FAU - Logozzi, M
AU  - Logozzi M
FAU - Belardelli, F
AU  - Belardelli F
LA  - eng
PT  - Congress
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (Interferon Type I)
SB  - IM
MH  - Cell Differentiation/*drug effects/immunology
MH  - Dendritic Cells/cytology/*drug effects/immunology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Immunotherapy/*methods/trends
MH  - Interferon Type I/*pharmacology
MH  - Monocytes/cytology/*drug effects/immunology
MH  - Signal Transduction/drug effects/immunology
EDAT- 2003/05/14 05:00
MHDA- 2004/02/28 05:00
CRDT- 2003/05/14 05:00
PHST- 2003/05/14 05:00 [pubmed]
PHST- 2004/02/28 05:00 [medline]
PHST- 2003/05/14 05:00 [entrez]
AID - 10.1634/stemcells.21-3-357 [doi]
PST - ppublish
SO  - Stem Cells. 2003;21(3):357-62. doi: 10.1634/stemcells.21-3-357.